Intervention Review

You have free access to this content

Oxytocin receptor antagonists for inhibiting preterm labour

  1. Vicki Flenady1,*,
  2. Hanna E Reinebrant1,
  3. Helen G Liley2,
  4. Eashan G Tambimuttu3,
  5. Dimitri NM Papatsonis4

Editorial Group: Cochrane Pregnancy and Childbirth Group

Published Online: 6 JUN 2014

Assessed as up-to-date: 1 DEC 2013

DOI: 10.1002/14651858.CD004452.pub3


How to Cite

Flenady V, Reinebrant HE, Liley HG, Tambimuttu EG, Papatsonis DNM. Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database of Systematic Reviews 2014, Issue 6. Art. No.: CD004452. DOI: 10.1002/14651858.CD004452.pub3.

Author Information

  1. 1

    Mater Research Institute - The University of Queensland (MRI-UQ), Translating Research Into Practice (TRIP) Centre, Brisbane, Queensland, Australia

  2. 2

    Mater Mothers’ Hospital, Mater Research, The University of Queensland, South Brisbane, Australia

  3. 3

    Royal Brisbane and Women's Hospital, Department of Gynaecology Oncology/Obstetrics and Gynaecology, Brisbane, Queensland, Australia

  4. 4

    Amphia Hospital Breda, Department of Obstetrics and Gynaecology, Breda, Netherlands

*Vicki Flenady, Translating Research Into Practice (TRIP) Centre, Mater Research Institute - The University of Queensland (MRI-UQ), Level 2 Aubigny Place, Mater Health Services, Annerley Road, Woolloongabba, Brisbane, Queensland, 4102, Australia. vflenady@mmri.mater.org.au.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 6 JUN 2014

SEARCH

[Figure 1]
Figure 1. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 2]
Figure 2. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 1 Birth less than 48 hours after trial entry.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 2 Perinatal mortality (stillbirth and neonatal death up to 28 days).
[Analysis 1.3]
Analysis 1.3. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 3 Stillbirth.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 4 Neonatal death.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 5 Infant death (up to 12 months).
[Analysis 1.6]
Analysis 1.6. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 6 Maternal death.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 7 Maternal adverse effects.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 8 Maternal adverse effects requiring cessation of treatment.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 9 Caesarean section.
[Analysis 1.10]
Analysis 1.10. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 10 Preterm birth (before completion of 37 weeks of gestation).
[Analysis 1.11]
Analysis 1.11. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 11 Extremely preterm birth (before completion of 28 weeks of gestation).
[Analysis 1.12]
Analysis 1.12. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 12 Gestational age (weeks).
[Analysis 1.13]
Analysis 1.13. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 13 Birthweight (grams).
[Analysis 1.14]
Analysis 1.14. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 14 Respiratory distress syndrome.
[Analysis 1.15]
Analysis 1.15. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 15 Intraventricular haemorrhage.
[Analysis 1.16]
Analysis 1.16. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 16 Necrotising enterocolitis.
[Analysis 1.17]
Analysis 1.17. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 17 Neonatal jaundice.
[Analysis 1.18]
Analysis 1.18. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 18 Admission to neonatal intensive care unit.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 1 Birth less than 48 hours after trial entry.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 2 Perinatal mortality.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 3 Very preterm birth (before completion of 34 weeks of gestation).
[Analysis 2.4]
Analysis 2.4. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 4 Stillbirth.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 5 Neonatal death.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 6 Maternal death.
[Analysis 2.7]
Analysis 2.7. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 7 Maternal adverse effects.
[Analysis 2.8]
Analysis 2.8. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 8 Maternal adverse effects requiring cessation of treatment.
[Analysis 2.9]
Analysis 2.9. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 9 Caesarean section.
[Analysis 2.10]
Analysis 2.10. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 10 Interval between trial entry and birth (days).
[Analysis 2.11]
Analysis 2.11. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 11 Preterm birth (before completion of 37 weeks of gestation).
[Analysis 2.12]
Analysis 2.12. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 12 Extremely preterm birth (before completion of 28 weeks of gestation).
[Analysis 2.13]
Analysis 2.13. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 13 Gestational age (weeks).
[Analysis 2.14]
Analysis 2.14. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 14 Birthweight (grams).
[Analysis 2.15]
Analysis 2.15. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 15 Apgar score less than 7 at 5 minutes.
[Analysis 2.16]
Analysis 2.16. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 16 Respiratory distress syndrome.
[Analysis 2.17]
Analysis 2.17. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 17 Use of mechanical ventilation.
[Analysis 2.18]
Analysis 2.18. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 18 Duration of mechanical ventilation (days).
[Analysis 2.19]
Analysis 2.19. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 19 Intraventricular haemorrhage.
[Analysis 2.20]
Analysis 2.20. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 20 Necrotising enterocolitis.
[Analysis 2.21]
Analysis 2.21. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 21 Retinopathy of prematurity.
[Analysis 2.22]
Analysis 2.22. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 22 Neonatal sepsis.
[Analysis 2.23]
Analysis 2.23. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 23 Admission to neonatal intensive care unit.
[Analysis 2.24]
Analysis 2.24. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 24 Neonatal length of hospital stay (days).